Breakthroughs in molecular engineering and antibody humanization, have resulted in monoclonal antibodies (mAbs) becoming one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications.
This highly competitive landscape necessitates the need for rapidly developing next-generation antibodies against new challenging targets with the improved mechanism of action, pharmacokinetics, and delivery system.
Current antibody screening tools such as ELISA only report on binding, one antigen at a time, hence they are time-consuming and utilize large amounts of the target protein. This application note highlights how the Intellicyt® iQue Screener platform enabled scientists at ModiQuest Research to significantly reduced their lead discovery time while conserving valuable samples and cutting down reagent cost.
Interested in learning more? Complete the form below to download the FREE application note!